Form 4: Celldex Therapeutics Director Denice Torres Granted 33,000 Stock Options

Celldex Therapeutics, Inc. director Denice Torres was granted 33,000 non-qualified stock options with an exercise price of $19.53, vesting in three equal annual installments starting June 5, 2026.

Summary

• Denice Torres, a Director of Celldex Therapeutics, Inc. (CLDX), was granted 33,000 non-qualified stock options.
• The options have an exercise price of $19.53 per share.
• The grant date for these options was June 5, 2025.
• The options will expire on June 5, 2035.
• Vesting of the options will occur in three equal annual installments, commencing on June 5, 2026.
• This grant was made pursuant to the Issuer's 2021 Omnibus Equity Incentive Plan.

Sentiment

Score: 6

Explanation: Slightly positive. This is a routine compensation disclosure that aligns director interests with shareholders, which is generally viewed favorably. It does not indicate any operational or financial issues.

Positives

• The grant of stock options to Director Denice Torres aligns her financial interests with those of the shareholders, incentivizing long-term company performance.
• The transaction is part of a pre-existing and approved 2021 Omnibus Equity Incentive Plan, indicating a structured approach to executive and director compensation.

Future Outlook

The vesting schedule indicates that the options will become exercisable in annual increments starting in June 2026, providing a future incentive for the director.

Industry Context

The granting of stock options to directors is a common practice in the biotechnology and pharmaceutical industries, serving as a key component of compensation packages designed to attract and retain talent while aligning leadership interests with shareholder value creation.

Comparison to Industry Standards

• The grant of stock options to directors is a standard compensation practice across publicly traded companies, particularly in growth-oriented sectors like biotechnology.
• The use of an Omnibus Equity Incentive Plan is typical for managing broad-based equity compensation programs, similar to those at companies like Amgen (AMGN) or Gilead Sciences (GILD) which also utilize such plans for their executives and directors.
• While the specific number of options and exercise price are unique to this grant, the structure of vesting over several years is consistent with industry norms aimed at fostering long-term commitment and performance.

Corporate Governance

Related Party Transactions

• The grant of stock options to Denice Torres, a director of Celldex Therapeutics, Inc., constitutes a related party transaction as it involves compensation from the company to a member of its board of directors.

Stakeholder Impact

• Shareholders: The grant of options to a director is intended to align the director's interests with those of the shareholders, potentially leading to better long-term performance and value creation.
• Employees: While this specific filing is about a director, such equity incentive plans are often part of broader compensation strategies that can also benefit employees, fostering a culture of shared ownership.

Next Steps

• The options will begin to vest in three equal annual installments starting June 5, 2026.

Key Dates

Keywords

Celldex Therapeutics, CLDX, Stock Option, Director Compensation, Equity Incentive Plan, Form 4, Insider Transaction, Non-Qualified Stock Option